Effects of the Endpoint Adjudication Process on the Results of a Randomised Controlled Trial: The ADVANCE Trial

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Hata, Jun ^a   Arima, Hisatomi ^a   Zoungas, Sophia ^a,b   Fulcher, Greg ^c   Pollock, Carol ^c   Adams, Mark ^d   Watson, John ^e   Joshi, Rohina ^a   Kengne, Andre Pascal ^a   Ninomiya, Toshiharu ^a   Anderson, Craig ^a   Woodward, Mark ^a   Patel, Anushka ^a   Mancia, Giuseppe ^f   Poulter, Neil ^g   MacMahon, Stephen ^a   Chalmers, John ^a   Neal, Bruce ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INDAPAMIDE PLUS PERINDOPRIL; PLACEBO;

ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; ENDPOINT ADJUDICATION PROCESS; HEART DEATH; HEART INFARCTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MASS SCREENING; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SUBARACHNOID HEMORRHAGE;

AGED; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DECISION MAKING; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; STROKE; TREATMENT OUTCOME;

EID: 84873508278     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055807     Document Type: Article

References (13)

1. ADVANCE Collaborative Group (2007) Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370: 829-840.
2. Granger CB, Vogel V, Cummings SR, Held P, Fiedorek F, et al. (2008) Do we need to adjudicate major clinical events? Clin Trials 5: 56-60.
3. Ninomiya T, Donnan G, Anderson N, Bladin C, Chambers B, et al. (2009) Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). Stroke 40: 2111-2115.
4. Pogue J, Walter SD, Yusuf S, (2009) Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 6: 239-251.
5. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, et al. (2001) Systematic adjudication of myocardial infarction end-points in an international clinical trial. Curr Control Trials Cardiovasc Med 2: 180-186.
6. Mahaffey KW, Harrington RA, Akkerhuis M, Kleiman NS, Berdan LG, et al. (2001) Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study. Curr Control Trials Cardiovasc Med 2: 187-194.
7. Petersen JL, Haque G, Hellkamp AS, Flaker GC, Mark Estes NA, 3rd et al. Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. Contemp Clin Trials 27: 260-268.
8. Cleland JG, Erhardt L, Hall AS, Winter C, Ball SG, et al. (1993) Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. J Cardiovasc Pharmacol 22(Suppl 9): S22-S27.
9. Näslund U, Grip L, Fischer-Hansen J, Gundersen T, Lehto S, et al. (1999) The impact of an end-point committee in a large multicentre, randomized, placebo-controlled clinical trial: results with and without the end-point committee's final decision on end-points. Eur Heart J 20: 771-777.
10. Mahaffey KW, Roe MT, Dyke CK, Newby LK, Kleiman NS, et al. (2002) Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J 143: 242-248.
11. Walter SD, Cook DJ, Guyatt GH, King D, Troyan S, et al. (1997) Outcome assessment for clinical trials: how many adjudicators do we need? Control Clin Trials 18: 27-42.
12. ADVANCE Management Committee (2001) Study rationale and design of ADVANCE: action in diabetes and vascular disease- preterax and diamicron MR controlled evaluation. Diabetologia 44: 1118-1120.
13. ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572.